GUTSFractyl Health Inc. Common Stock

Fractyl Health (NASDAQ:GUTS) is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer Harith Rajagopalan said during a Canaccord discussion. The company’s lead program, Revita, uses an ou

Moby summary of Fractyl Health, Inc. Common Stock's Q2 2026 earnings call

Fractyl Health Inc (GUTS) reports strong REMAIN-1 results, a clear regulatory path for Revita, and a cash runway into early 2027.

Fractyl Health (NASDAQ:GUTS) said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission l

GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients.

Fractyl Health (NASDAQ:GUTS) reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced weight loss after discontinuing GLP-1 therapy compared with a sham procedure. On the company’s data cal